TABLE 2.
Function and PA no. | Master no. | Gene name | Gene product | Level of abundanceb | Fold modulation |
---|---|---|---|---|---|
Spots displaying increased abundance in the wild-type (PAO1) secretome | |||||
PA2783 | 1426 | mep72 | Metzincin protease Mep72 | ↑ | 55.8 |
PA2783 | 1421 | mep72 | Metzincin protease Mep72 | ↑ | 21.6 |
PA1706 | 1483 | pcrV | Type III secretion protein PcrV | ↑ | 7.9 |
PA1094 | 810 | fliD | Flagella capping protein FliD | ↑ | 7.6 |
PA2783 | 880 | mep72 | Metzincin protease Mep72 | ↑ | 7.2 |
Spots displaying decreased abundance in the wild-type (PAO1) secretome | |||||
PA1709 | 1401 | popD | Type III secretion protein PopD | ↓ | 7.1 |
PA3841 | 757 | exoS | Type III secretion effector ExoS | ↓ | 5.1 |
PA3841/PA0044 | 751 | exoS-exoT | Type III secretion effector ExoS/ExoT | ↓ | 3.8 |
Summary of the identified protein spots modulated in the PAO1 secretome compared to their activity in the mep72 mutant secretome. While LC-MS/MS analysis identified spot 757 as ExoS, spot 751 was identified as either ExoS or ExoT. Given that ExoS and ExoT share 74% amino acid sequence homology, many of the peptide sequences retrieved following trypsin digestion are almost identical. In these circumstances, ExoS and ExoT cannot be distinguished from each other.
↑ and ↓ arrows indicate whether the spot was more or less abundant in the PAO1 secretome than in the mep72 mutant secretome.